SCHEMBL6299444

SCHEMBL6299444

CCOc1ccc(C(=O)Nc2ccc3c(c2)CN(C)CC3)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 6/20 0.63
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 2/20 0.57
POLB P06746 2/20 0.57
GAA P10253 1/20 0.57
MCL1 Q07820 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
CYP3A4 P08684 1/20 0.57
MAPT P10636 7/20 0.54
ALDH1A1 P00352 3/20 0.54
TP53 P04637 3/20 0.52
ALOX15 P16050 1/20 0.52
ALOX12 P18054 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7802384 0.94 MEN1 (0.58) ROCK2MEN1KMT2ALMNAPOLB
SCHEMBL307810 0.90 ROCK2 (0.75) ROCK2CYP3A4ROCK1
SCHEMBL6717820 0.89 MEN1 (0.56) ROCK2MEN1KMT2ALMNAGAA
SCHEMBL6293954 0.89 ROCK2 (0.77) ROCK2MEN1KMT2APOLBSMN1; SMN2
SCHEMBL6293914 0.88 MAPT (0.68) ROCK2MEN1KMT2ALMNAPOLB
SCHEMBL6299445 0.87 ROCK2 (0.56) ROCK2SMN1; SMN2CYP3A4MAPTTP53
SCHEMBL6293739 0.87 ROCK2 (0.69) ROCK2CYP3A4RORCROCK1TMPRSS2
SCHEMBL7951842 0.86 MEN1 (0.53) ROCK2MEN1KMT2ALMNAPOLB
Hydrochloric Acid SCHEMBL8134734 0.85 MEN1 (0.53) ROCK2MEN1KMT2ALMNAPOLB
SCHEMBL6294916 0.85 ROCK2 (0.54) ROCK2MEN1KMT2ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US claimed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US claimed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 US claimed
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 US disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US disclosed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A ROCK2 2314/4885MEN1 3408/4885KMT2A 445/4885
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A ROCK2 2314/4885MEN1 3408/4885KMT2A 445/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 ROCK2 4693/4885MEN1 269/4885KMT2A 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.